Germany Infectious Disease Molecular Diagnostics Market Size & Outlook
The infectious disease molecular diagnostics market in Germany is expected to reach a projected revenue of US$ 588.2 million by 2030. A compound annual growth rate of 3.1% is expected of Germany infectious disease molecular diagnostics market from 2025 to 2030.
Clinical Diagnostics
In Vitro Diagnostics
Infectious Disease Molecular Diagnostics Market Outlook
The Germany infectious disease molecular diagnostics market generated a revenue of USD 488.9 million in 2024 and is expected to reach USD 588.2 million by 2030.
The Germany market is expected to grow at a CAGR of 3.1% from 2025 to 2030.
In terms of segment, reagents product was the largest revenue generating product in 2024.
Others Product is the most lucrative product segment registering the fastest growth during the forecast period.
Infectious disease molecular diagnostics market data book summary
Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp
Other key industry trends
In terms of revenue, Germany accounted for 3.1% of the global infectious disease molecular diagnostics market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, UK infectious disease molecular diagnostics market is projected to lead the regional market in terms of revenue in 2030.
UK is the fastest growing regional market in Europe and is projected to reach USD 716.2 million by 2030.
In Germany, the incidence rate for hospital-acquired infections is 3.79 per 1,000 patient days in the public hospitals. This included infections such catheter-associated urinary tract infections, catheter-associated infections, and Ventilatoracquired Pneumonia (VAP).
These healthcare-associated infections are drug resistant, hence, use of molecular diagnostics facilitates selection of treatment. Furthermore, Germany has a strong healthcare system, which covers 90% of the population under the mandatory health insurance cover, enabling easy access to molecular diagnostics.
The most commonly diagnosed infections in the country are UTIs and acute upper respiratory tract infections. The country records over 75,000 cases of sepsis each year in the ICUs. Furthermore, STI prevalence is growing in the country, with Mycoplasma genitalium having a prevalence rate of 18.8%, followed by chlamydia at 12.7%.
Germany Infectious Disease Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Infectious Disease Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Reagents Product was the largest segment with a revenue share of 67.62% in 2024.
Horizon Databook has segmented the Germany infectious disease molecular diagnostics market based on instruments product, reagents product, others product covering the revenue growth of each sub-segment from 2018 to 2030.
In Germany, the incidence rate for hospital-acquired infections is 3.79 per 1,000 patient days in the public hospitals. This included infections such catheter-associated urinary tract infections, catheter-associated infections, and Ventilatoracquired Pneumonia (VAP).
These healthcare-associated infections are drug resistant, hence, use of molecular diagnostics facilitates selection of treatment. Furthermore, Germany has a strong healthcare system, which covers 90% of the population under the mandatory health insurance cover, enabling easy access to molecular diagnostics.
The most commonly diagnosed infections in the country are UTIs and acute upper respiratory tract infections. The country records over 75,000 cases of sepsis each year in the ICUs. Furthermore, STI prevalence is growing in the country, with Mycoplasma genitalium having a prevalence rate of 18.8%, followed by chlamydia at 12.7%.
Germany Infectious Disease Molecular Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
Instruments Product
Reagents Product
Services Product
Germany Infectious Disease Molecular Diagnostics Market Test location Outlook (Revenue, USD Million , 2018-2030)
Hospitals
Clinics
Diagnostics Laboratories
Research Institutes
Germany Infectious Disease Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2018-2030)
Germany Infectious Disease Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2018-2030)
Respiratory Diseases
Tuberculosis
Meningitis
Gastrointestinal Tract Infections
HPV
Sexually Transmitted Infection
Sepsis
Drug Resistance Disease
Others Application
Reasons to subscribe to Infectious Disease Molecular Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Infectious Disease Molecular Diagnostics Market Outlook databook
Our clientele includes a mix of Infectious Disease Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Infectious Disease Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Infectious Disease Molecular Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.